Think the Drug-Pricing debate addresses Patient Costs? Think again.

Writing for The Hill, BIO President and CEO Jim Greenwood tackled the drug pricing debate in Washington and touched on President Trump’s proposals for lowering drug prices.
On the Administration’s recent International Pricing Index (IPI), which would move from a market-based payment formula for Medicare Part B drugs to one based on foreign prices, Greenwood explains:
“Importing foreign price controls will take a wrecking ball to our global leadership in drug innovation. It may